Accueil   Diary - News   All news A disruptive technology to produce an innovative antimicrobial treatment for Cystic Fibrosis

A disruptive technology to produce an innovative antimicrobial treatment for Cystic Fibrosis

 

 

Lyon (France), 24 January 2019 – A strategic milestone of the project ALX-009 has now been completed: Lyon-based biotech company Alaxia announces the start of production of its innovative device dedicated to the extemporaneous production of its drug candidate ALX-009. In an incredible timeframe, Alaxia has overcome the challenge of developing an intuitive and fully automated portable device. The production is now running since early January 2019. This innovative device was a must to give independent access to ALX-009 to patients, indeed it has been designed to allow full secure use by patients at home or by healthcare professionals. This will facilitate the pharmaceutical and clinical development of ALX-009.

 

Lire le communiqué de presse

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree